Press Releases Orchestra BioMed Holdings, Inc.

Equities

OBIO

US68572M1062

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
4.71 ^USD	-4.85%		-7.65%	-48.41%

Apr. 30	Orchestra BioMed Holdings, Inc. Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents	CI
Mar. 27	Orchestra BioMed Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents	Apr. 30	GL
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024	Apr. 30	GL
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024	Apr. 30	AQ
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update	Mar. 27	GL
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors	Mar. 26	GL
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting	Mar. 13	GL
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting	Mar. 13	AQ
Orchestra BioMed to Participate in Upcoming Investor Conferences	Mar. 07	GL
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients	Mar. 06	GL
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years	Feb. 26	GL
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years	Feb. 26	AQ
Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients	Jan. 08	AQ
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 13	GL
Orchestra BioMed to Present at Upcoming Investor Conferences	Nov. 09	AQ
Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients	23-09-19	GL
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update	23-08-10	GL
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis	23-08-08	GL
Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes	23-06-26	GL
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer	23-06-07	GL
Orchestra BioMed to Present at the Jefferies Global Healthcare Conference	23-06-01	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Orchestra BioMed Holdings, Inc.

Equities

OBIO

US68572M1062

Press Releases

Filters